Inclusion Criteria:

- Have a histopathologically confirmed diagnosis of metastatic gastric or
gastroesophageal junction (GEJ) adenocarcinoma. All histologies of nonsquamous cell
origin including undifferentiated gastric carcinoma are eligible.

- Have not received any prior first-line systemic therapy (prior adjuvant or
neo-adjuvant therapy is permitted). Participants whose disease has progressed after
>12 months following the last dose of systemic treatment in the adjuvant/neoadjuvant
setting are eligible.

- Have measurable or nonmeasurable but evaluable disease determined using guidelines in
Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1). Baseline
tumor assessment should be performed using a high resolution computed tomography (CT)
scan using IV and oral contrast unless clinically contra-indicated. Magnetic
resonance imaging (MRI) is acceptable if a CT cannot be performed.

- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale
at baseline.

- Have adequate organ function.

- Have baseline clinical and laboratory parameters that are consistent with the
requirements prescribed in respective labels and are suitable for consideration of
treatment with capecitabine (or 5-FU) and cisplatin (for example, dihydropyrimidine
dehydrogenase deficiency).

- Have an estimated life expectancy of 12 weeks in the judgment of the investigator.

Exclusion Criteria:

- Participants with adenocarcinoma of the esophagus are excluded.

- Participants with human epidermal growth factor receptor 2 (HER2)-positive status.

- Participants receiving chronic therapy with nonsteroidal anti-inflammatory agents.

- Have radiation therapy within 14 days prior to randomization.

- Have documented brain metastases, leptomeningeal disease or uncontrolled spinal cord
compression.

- Have significant bleeding disorders, vasculitis, or had a significant bleeding
episode from the gastrointestinal tract within 12 weeks prior to randomization.

- Have experienced any arterial thromboembolic event, including myocardial infarction,
unstable angina, cerebrovascular accident, or transient ischemic attack, within 6
months prior to randomization.

- Have symptomatic congestive heart failure (New York Heart Association II-IV) or
symptomatic or poorly controlled cardiac arrhythmia.

- Have uncontrolled hypertension prior to initiating study treatment, despite
antihypertensive intervention.

- Have undergone major surgery within 28 days prior to randomization, or central venous
access device placement within 7 days prior to first dose of study treatment, except
if the procedure is minimally invasive (for example, introduction of peripherally
inserted central catheter [PICC] line) and the investigator does not anticipate any
significant bleeding.

- Have a history of gastrointestinal perforation and/or fistulae within 6 months prior
to randomization.

- Have a history of inflammatory bowel disease or Crohn's disease requiring medical
intervention (immunomodulatory or immunosuppressive medications or surgery) 12
months prior to randomization.

- Have an acute or subacute bowel obstruction or history of chronic diarrhea which is
considered clinically significant in the opinion of the investigator.

- The participant has:

- cirrhosis at a level of Child-Pugh B (or worse) or

- cirrhosis (any degree) and a history of hepatic encephalopathy or clinically
meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is
defined as ascites resulting from cirrhosis and requiring ongoing treatment with
diuretics and/or paracentesis.

- Have known allergy or hypersensitivity to any components of study treatment.

- Are pregnant or lactating.

Minimum Eligible Age: 18 Years

Maximum Eligible Age: N/A

Eligible Gender: Both